---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-250984"
form_type: "8-K"
ticker: "KPTI"
cik: "0001503802"
company_name: "Karyopharm Therapeutics Inc."
filed_at: "2024-11-05T23:59:59+00:00"
generated_at: "2026-05-30T05:18:28.616395+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Karyopharm Q3 total revenue $38.8M, net loss $32.1M; narrows FY2024 guidance

## Summary
- U.S. XPOVIO net product revenue $29.5M in Q3, down from $30.2M in Q3 2023; total revenue up to $38.8M from $36.0M.
- Net loss $32.1M ($0.26/share) vs $34.5M ($0.30/share) in Q3 2023; R&D expenses increased to $36.1M.
- FY2024 total revenue guidance narrowed to $145-155M; XPOVIO revenue guidance narrowed to $110-115M.
- Phase 3 SENTRY myelofibrosis trial endpoint changed to Abs-TSS; sample size increased to ~350; top-line data expected 2H 2025.
- Cash and investments $133.9M; cash runway into Q1 2026 (excluding $24.5M convertible note due Oct 2025).

## SEC filing metadata
- accession: 0001193125-24-250984
- form_type: 8-K
- ticker: KPTI
- cik: 0001503802
- company_name: Karyopharm Therapeutics Inc.
- filed_at: 2024-11-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1503802/000119312524250984/0001193125-24-250984-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1503802/000119312524250984/d906207d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-250984
- JSON: https://secwatch.observer/filing/0001193125-24-250984.json
- Plain text: https://secwatch.observer/filing/0001193125-24-250984.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.